



29 October 2025

dorsaVi Initiates Analysis for Scaling Down To 22 nm RRAM

**Engagement with potential semiconductor development partners
commenced**

Highlights

- **Initiated process to secure a semiconductor development partner to assess scalability of dorsaVi's oxide-based RRAM beyond the current 40 nm process.**
- **Planned evaluation program to model performance, reliability, and manufacturability outcomes at smaller nodes, targeting faster switching and reduced energy per operation.**
- **22 nm node remains one of the industry's most manufacturable memory geometries, ideal for non-volatile memory where embedded Flash is no longer viable**

Melbourne, Australia, 29 October 2025: dorsaVi Limited (ASX: DVL) (“**dorsaVi**” or “**the Company**”) a leader in FDA-approved wearable sensor technologies and motion intelligence, is pleased to announce it has commenced engagement with potential semiconductor development partners to explore the scaling down of its oxide-based Resistive Random-Access Memory (RRAM) technology toward the 22 nm process node.

This initiative follows the successful validation of the Company's 40 nm RRAM architecture through its Artemis Labs program, where early results demonstrated reliable, high-speed switching and strong endurance across multiple wafers. Advancing towards smaller nodes represents a natural evolution of this technology, unlocking opportunities for greater density, faster switching, and reduced power consumption, key parameters for integration into next-generation edge and wearable computing systems.

The 22 nm node is one of the industry's most widely supported, production-ready platforms, offering an ideal balance of manufacturability and performance. For dorsaVi, it provides a strong foundation for adaptive, oxide-based RRAM arrays that must deliver local intelligence in biosensing, prosthetics, and robotics where cloud dependence and latency aren't acceptable.

Pending the conclusion of partner selection and feasibility scoping, dorsaVi intends to establish a joint evaluation plan covering device performance, reliability, and integration at 22 nm. Those results will guide the next test-chip design and potential foundry engagement.

Gernot Abl, Chairman of dorsaVi, said: “Scaling our RRAM platform to smaller memory geometries marks an important step in transforming our sensor and robotics products into adaptive, intelligent systems. Discussions with global semiconductor partners are underway to ensure that as we move down to 22 nm, our technology remains manufacturable, efficient, and aligned with industry-standard process flows.”

This release has been authorised for lodgement to the ASX by the Board.

- ENDS -

For further information about dorsaVi, please contact:

Gernot Abl Chairman +61 419 802 653 Email: ga@dorsaVi.com	Andrew Ronchi Chief Executive Officer +61 417 882 267 Email: ar@dorsaVi.com
--	--

About dorsaVi

dorsaVi Ltd (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi’s focus is on two major markets:

- **Workplace:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company’s customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Boeing, Monash Health, Coles, Woolworths, Toll, Toyota, Orora, Mineral Resources and BHP Billiton.
- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions (ViMove+) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refer to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at www.dorsaVi.com